Targeted kinase inhibitors (TKI) are among the most successful targeted cancer therapies. However, TKIs simultaneously inhibit several human protein kinases, often causing undesirable off-target toxicity. Together with his research group at Berlin Institute of Health, the renowned chemist and biophysicist John Chodera works on increasing the effectiveness of TKIs, making an important contribution to the treatment of cancer. Chodera, who has previously worked at University of California, Berkeley, and Stanford University, is now an Associate Professor for Physiology, Biophysics and Systems Biology at Memorial Sloan-Kettering Cancer Center in New York.
About us
The Einstein Foundation Berlin was founded in 2009 by the State of Berlin. The Foundation funds cutting-edge science and research in Berlin and helps to strengthen the city's reputation as one the world's foremost research hotspots.
Follow us on